VRCA Verrica Pharmaceuticals Inc.: Business Value to Revenue

Public company logo of Verrica Pharmaceuticals (VRCA)

The price-to-sales multiple dynamics of Verrica Pharmaceuticals (VRCA) are comparable to the implementation of ESG standards and ethical waste disposal, while the 2008.74 level records fresh values. Verrica Pharmaceuticals (VRCA) develops high-precision drug delivery systems to combat skin viruses, which facilitates the active expansion of its client base among American pediatricians and dermatologists.

VRCA Verrica Pharmaceuticals Inc.: EV/Sales Multiple in the range 11/23/2025 - 11/21/2026

Financial and market metric breakdowns for Verrica Pharmaceuticals Inc. (VRCA)

- company stock capitalization data:
Initial company analysis:Verrica Pharmaceuticals Inc
Mass-produced product of verrica.com

Amidst a liquidity shortage driven by expansion costs for the drug from Verrica Pharmaceuticals (VRCA), the company's enterprise value-to-revenue ratio allows for an assessment of the business's market multiple while excluding the impact of debt load. This indicator compares the total value of assets with sales volume, helping investors determine the degree of asset overvaluation and assess the risk of prices falling below statistical norms as reserves continue to be depleted.